246
Views
25
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma

, , , , , & show all
Pages 298-305 | Received 26 Mar 2007, Accepted 20 Oct 2007, Published online: 01 Jul 2009
 

Abstract

The aim of this prospective, long-term study was to define the flow cytometric characteristics of plasma cell CD56 expression as well as determine the clinical characteristics of 204 multiple myeloma (MM) patients and 26 plasma cell leukemia (PCL) patients with regard to CD56 expression. CD56 expression intensity was determined by measurement of antigen molecules on the cell defined as Antibodies Bound per Cell (ABC) and calculation of Relative Fluorescence Intensity (RFI). CD56 expression was found in 66% of MM and 54% of PCL cases. The RFI values for individual MM patients ranged from 7.6 to 27.4 while ABC values on MM plasma cells from 2255 to 58469. There was a correlation between the proportion of all bone marrow CD38++/CD138+ cells with CD56 expression and ABC and RFI indices. With regard to CD56 expression positive patients, the CD56 MM patients presented lower frequency of osteolysis (p = 0.01). The median survival was 48 months in CD56+ patients and 43 months (p = 0.84) in CD56 cases. In conclusion, CD56 expression carries no distinct adverse prognosis and the lack of CD56 expression does not define a unique clinicopathological or prognostic entity in MM. A remarkable heterogeneity of CD56 expression intensity in CD56+ patients imposes the necessity of determining CD56 expression intensity in candidates to antibody-based therapy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.